Related Experiment Videos
Antiestrogens specifically up-regulate bone morphogenetic protein-4 promoter activity in human osteoblastic cells
A van den Wijngaard1, W R Mulder, R Dijkema
1Department of Applied Biology, University of Nijmegen, The Netherlands.
Molecular Endocrinology (Baltimore, Md.)
|May 16, 2000
Summary
Antiestrogens specifically stimulate bone morphogenetic protein-4 (BMP-4) promoter activity in bone cells, independent of estrogen-responsive elements. This finding offers potential new strategies for treating osteoporosis and other bone diseases.
Area of Science:
- Endocrinology
- Molecular Biology
- Bone Biology
Background:
- Bone morphogenetic protein-4 (BMP-4) is crucial for endochondral bone formation.
- Reduced BMP-4 expression is linked to various bone diseases.
Purpose of the Study:
- To investigate the regulation of the human BMP-4 promoter by steroid hormones.
- To explore the role of estrogen receptor subtypes in BMP-4 gene expression.
Main Methods:
- Transient transfection assays were performed in bone cells.
- The activity of the human BMP-4 promoter was analyzed.
- The effects of antiestrogens, estrogens, and estrogen receptor subtypes (ER-alpha and ER-beta) were evaluated.
Main Results:
- The human BMP-4 promoter was specifically stimulated by antiestrogens, not estrogens or other steroid hormones.
- This stimulation was dependent on estrogen receptor alpha (ER-alpha), despite the absence of a consensus estrogen-responsive element.
- No activity was observed with ER-beta alone, but synergy occurred when both ER subtypes were co-transfected.
- Antiestrogen-induced BMP-4 promoter activity was bone cell-specific and reversible by estrogens.
Conclusions:
- Antiestrogens can specifically activate BMP-4 gene expression in bone cells via ER-alpha.
- This mechanism offers a novel pathway for therapeutic intervention in bone diseases.
- Findings suggest potential for developing new osteoporosis treatments targeting BMP-4 regulation.